Hyperion Therapeutics Rating Reiterated by JMP Securities (HPTX)
Hyperion Therapeutics (NASDAQ:HPTX)‘s stock had its “market outperform” rating reiterated by research analysts at JMP Securities in a report released on Friday, American Banking and Market News reports. They currently have a $35.00 price target on the stock, up from their previous price target of $30.00. JMP Securities’ target price would suggest a potential upside of 34.72% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Needham & Company reiterated a “buy” rating on shares of Hyperion Therapeutics (NASDAQ:HPTX) in a research note to investors on Thursday, August 15th. They now have a $35.00 price target on the stock, up previously from $25.00. Separately, analysts at Zacks downgraded shares of Hyperion Therapeutics (NASDAQ:HPTX) from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, August 7th. They now have a $28.20 price target on the stock. Finally, analysts at Zacks upgraded shares of Hyperion Therapeutics (NASDAQ:HPTX) from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, July 9th. They now have a $24.30 price target on the stock.
One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. Hyperion Therapeutics has a consensus rating of “Hold” and an average target price of $32.80.
Hyperion Therapeutics (NASDAQ:HPTX) traded up 0.73% during mid-day trading on Friday, hitting $26.17. The stock had a trading volume of 115,104 shares. Hyperion Therapeutics has a 52 week low of $10.00 and a 52 week high of $28.34. The stock has a 50-day moving average of $24.96 and a 200-day moving average of $23.07. The company has a market cap of $525.7 million and a P/E ratio of 159.39.
Hyperion Therapeutics (NASDAQ:HPTX) last released its earnings data on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.05. The company had revenue of $7.30 million for the quarter, compared to the consensus estimate of $2.17 million.
In other Hyperion Therapeutics news, major shareholder Highland Management Partners V unloaded 34,573 shares of the company’s stock on the open market in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $26.56, for a total transaction of $918,258.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Hyperion Therapeutics, Inc (NASDAQ:HPTX)is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.